Vifor Pharma comments on media speculationST. GALLEN, Switzerland (BUSINESS WIRE) Regulatory News:AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LRVifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on thes.
Agreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent to CHF167 per share1
. 10, 2021 06:00 UTCVifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury ST. GALLEN, Switzerland & UNIONDALE, N.Y. (BUSINESS WIRE) Regulatory News:This press release features multimedia. View the full release here: https://.
Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on these discussions.
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult patients with sickle cell disease.